Page 226 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 12 Cancer Chemotherapy 205

260. Huang P, Plunkett W: Fludarabine- and gemcitabine-induced 280. Santi DV, McHenry CS, Sommer H: Mechanism of interaction of
apoptosis: incorporation of analogs into DNA is a critical event, thymidylate synthetase with 5-fluorodeoxyuridylate, Biochemistry
Cancer Chemother Pharmacol 36:181–188, 1995. 13:471–481, 1974.
VetBooks.ir 261. Veltkamp SA, Pluim D, van Eijndhoven MA, et al.: New insights 281. Naguib FN, el Kouni MH, Cha S: Enzymes of uracil catabolism in
normal and neoplastic human tissues, Cancer Res 45:5405–5412,
into the pharmacology and cytotoxicity of gemcitabine and
1985.
2′,2′-difluorodeoxyuridine, Mol Cancer Ther 7:2415–2425, 2008.
262. Veltkamp SA, Jansen RS, Callies S, et al.: Oral administration of 282. Grem JL: 5-Fluoropyrimidines. In Chabner BA, Longo DL, edi-
gemcitabine in patients with refractory tumors: a clinical and phar- tors: Cancer chemotherapy & biotherapy: principles and practice, ed 3,
macologic study, Clin Cancer Res 14:3477–3486, 2008. Philadelphia, 2001, Lippincott Williams & Wilkins, pp 185–264.
263. Veltkamp SA, Pluim D, van Tellingen O, et al.: Extensive metab- 283. Snavely NR, Snavely DA, Wilson BB: Toxic effects of fluorouracil cream
olism and hepatic accumulation of gemcitabine after multiple ingestion on dogs and cats, Arch Dermatol 146:1195–1196, 2010.
oral and intravenous administration in mice, Drug Metab Dispos 284. Rose WC, Crosswell AR, Bronson JJ, et al.: In vivo antitumor activ-
36:1606–1615, 2008. ity of 9-[(2-phosphonylmethoxy)ethyl]-guanine and related phos-
264. Tempero M, Plunkett W, Ruiz Van Haperen V, et al.: Randomized phonate nucleotide analogues, J Natl Cancer Inst 82:510–512, 1990.
phase II comparison of dose-intense gemcitabine: thirty-minute 285. Reiser H, Wang J, Chong L, et al.: Gs-9219—a novel acyclic nucle-
infusion and fixed dose rate infusion in patients with pancreatic otide analogue with potent antineoplastic activity in dogs with
adenocarcinoma, J Clin Oncol 21:3402–3408, 2003. spontaneous non-Hodgkin’s lymphoma, Clin Cancer Res 14:2824–
265. Turner AI, Hahn KA, Rusk A, et al.: Single agent gemcitabine che- 2832, 2008.
motherapy in dogs with spontaneously occurring lymphoma, J Vet 286. Compton ML, Toole JJ, Paborsky LR: 9-(2-Phosphonylmethoxyethyl)-
6
Intern Med 20:1384–1388, 2006. N -cyclopropyl-2,6-diaminopurine (CPR-PMEDAP) as a prodrug
266. Marconato L, Zini E, Lindner D, et al.: Toxic effects and antitumor of 9-(2-phosphonylmethoxyethyl)guanine (PMEG), Biochem Phar-
response of gemcitabine in combination with piroxicam treatment macol 58:709–714, 1999.
in dogs with transitional cell carcinoma of the urinary bladder, 287. Naesens L, Hatse S, Segers C, et al.: 9-(2-Phosphonylmethoxyethyl)-
J Am Vet Med Assoc 238:1004–1010, 2011. N -cyclopropyl-2,6-diaminopurine: a novel prodrug of
6
267. McMahon M, Mathie T, Stingle N, et al.: Adjuvant carboplatin 9-(2- phosphonylmethoxyethyl)guanine with improved antitumor
and gemcitabine combination chemotherapy postamputation in efficacy and selectivity in choriocarcinoma-bearing rats, Oncol Res
canine appendicular osteosarcoma, J Vet Intern Med 25:511–517, 11:195–203, 1999.
2011. 288. Ho HT, Woods KL, Konrad SA, et al.: Cellular metabolism and
268. Marconato L, Lorenzo RM, Abramo F, et al.: Adjuvant gem- enzymatic phosphorylation of 9-(2-phosphonylmethoxyethyl) gua-
citabine after surgical removal of aggressive malignant mammary nine (PMEG), a potent antiviral agent, Adv Exp Med Biol 312:159–
tumours in dogs, Vet Comp Oncol 6:90–101, 2008. 166, 1992.
269. Elpiner AK, Brodsky EM, Hazzah TN, et al.: Single-agent gem- 289. Kramata P, Votruba I, Otova B, et al.: Different inhibitory poten-
citabine chemotherapy in dogs with hepatocellular carcinomas, Vet cies of acyclic phosphonomethoxyalkyl nucleotide analogs toward
Comp Oncol 9:260–268, 2011. DNA polymerases alpha, delta and epsilon, Mol Pharmacol
270. McMahon M, Mathie T, Stingle N, et al.: Adjuvant carboplatin 49:1005–1011, 1996.
and gemcitabine combination chemotherapy postamputation in 290. Morges MA, Burton JH, Saba CF, et al.: Phase II evaluation of
canine appendicular osteosarcoma, J Vet Intern Med 25:511–517, VDC-1101 in canine cutaneous T-cell lymphoma, J Vet Intern Med
2011. 28:1569–1574, 2014.
271. Dominguez PA, Dervisis NG, Cadile CD, et al.: Combined gem- 291. Thamm DH, Vail DM, Kurzman ID, et al.: GS-9219/VDC-
citabine and carboplatin therapy for carcinomas in dogs, J Vet 1101—a prodrug of the acyclic nucleotide PMEG has antitumor
Intern Med 23:130–137, 2009. activity in spontaneous canine multiple myeloma, BMC Vet Res
272. Martinez-Ruzafa I, Dominguez PA, Dervisis NG, et al.: Tolerabil- 10:30, 2014.
ity of gemcitabine and carboplatin doublet therapy in cats with 292. Thamm DH, Vail DM, Post GS, et al.: Alternating rabacfosadine/
carcinomas, J Vet Intern Med 23:570–577, 2009. doxorubicin: efficacy and tolerability in naive canine multicentric
273. LeBlanc AK, LaDue TA, Turrel JM, et al.: Unexpected toxicity fol- lymphoma, J Vet Intern Med 31:872–878, 2017.
lowing use of gemcitabine as a radiosensitizer in head and neck car- 293. Vail DM, Thamm DH, Reiser H, et al.: Assessment of GS-9219
cinomas: a veterinary radiation therapy oncology group pilot study, in a pet dog model of non-Hodgkin’s lymphoma, Clin Cancer Res
Vet Radiol Ultrasound 45:466–470, 2004. 15:3503–3510, 2009.
274. Wohlhueter RM, McIvor RS, Plagemann PG: Facilitated transport 294. Saba CF, Vickery KR, Clifford CA, et al.: Rabacfosadine for
of uracil and 5-fluorouracil, and permeation of orotic acid into cul- relapsed canine B-cell lymphoma: efficacy and adverse event pro-
tured mammalian cells, J Cell Physiol 104:309–319, 1980. files of 2 different doses, Vet Comp Oncol 16:E76–E82, 2018.
275. Reyes P: The synthesis of 5-fluorouridine 5′-phosphate by a pyrim- 295. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly
idine phosphoribosyltransferase of mammalian origin. I. Some in vitro by taxol, Nature 277:665–667, 1979.
properties of the enzyme from p1534j mouse leukemic cells, Bio- 296. Schiff PB, Horwitz SB: Taxol stabilizes microtubules in mouse
chemistry 8:2057–2062, 1969. fibroblast cells, Proc Natl Acad Sci USA 77:1561–1565, 1980.
276. Houghton JA, Houghton PJ: Elucidation of pathways of 5-fluoro- 297. Ringel I, Horwitz SB: Studies with RP 56976 (taxotere): a semisyn-
uracil metabolism in xenografts of human colorectal adenocarci- thetic analogue of taxol, J Natl Cancer Inst 83:288–291, 1991.
noma, Eur J Cancer Clin Oncol 19:807–815, 1983. 298. Jordan MA, Toso RJ, Thrower D, et al.: Mechanism of mitotic
277. Kufe DW, Major PP: 5-Fluorouracil incorporation into human block and inhibition of cell proliferation by taxol at low concentra-
breast carcinoma rna correlates with cytotoxicity, J Biol Chem tions, Proc Natl Acad Sci USA 90:9552–9556, 1993.
256:9802–9805, 1981. 299. Bissery MC, Guenard D, Gueritte-Voegelein F, et al.: Experimental
278. Kufe DW, Major PP, Egan EM, et al.: 5-Fluoro-2′-deoxyuridine antitumor activity of taxotere (RP 56976, NSC 628503), a taxol
incorporation in l1210 DNA, J Biol Chem 256:8885–8888, 1981. analogue, Cancer Res 51:4845–4852, 1991.
279. Tanaka M, Yoshida S, Saneyoshi M, et al.: Utilization of 5-fluoro- 300. Diaz JF, Andreu JM: Assembly of purified gdp-tubulin into micro-
2′-deoxyuridine triphosphate and 5-fluoro-2′-deoxycytidine tri- tubules induced by taxol and taxotere: reversibility, ligand stoichi-
phosphate in DNA synthesis by DNA polymerases alpha and beta ometry, and competition, Biochemistry 32:2747–2755, 1993.
from calf thymus, Cancer Res 41:4132–4135, 1981.